Vessel co‐option in primary human tumors and metastases: an obstacle to effective anti‐angiogenic treatment?

Cancer Medicine - Tập 2 Số 4 - Trang 427-436 - 2013
Tom Dønnem1,2, Jiangting Hu3, Mary Ferguson3, Omanma Adighibe3, Cameron Snell3, Adrian L. Harris4,3, Kevin C. Gatter3, Francesco Pezzella3
1Department of Oncology, University Hospital of North Norway, Tromso, Norway
2Institute of Clinical Medicine, University of Tromso, Tromso, Norway
3Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
4Department of Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom

Tóm tắt

AbstractAngiogenesis has been regarded as essential for tumor growth and progression. Studies of many human tumors, however, suggest that their microcirculation may be provided by nonsprouting vessels and that a variety of tumors can grow and metastasize without angiogenesis. Vessel co‐option, where tumor cells migrate along the preexisting vessels of the host organ, is regarded as an alternative tumor blood supply. Vessel co‐option may occur in many malignancies, but so far mostly reported in highly vascularized tissues such as brain, lung, and liver. In primary and metastatic lung cancer and liver metastasis from different primary origins, as much as 10–30% of the tumors are reported to use this alternative blood supply. In addition, vessel co‐option is introduced as a potential explanation of antiangiogenic drug resistance, although the impact of vessel co‐option in this clinical setting is still to be further explored. In this review we discuss tumor vessel co‐option with specific examples of vessel co‐option in primary and secondary tumors and a consideration of the clinical implications of this alternative tumor blood supply.

Từ khóa


Tài liệu tham khảo

10.1016/j.cell.2011.02.013

10.1016/S0959-8049(96)00377-2

Pezzella F., 1997, Non‐small‐cell lung carcinoma tumor growth without morphological evidence of neo‐angiogenesis, Am. J. Pathol., 151, 1417

10.1038/sj.bjc.6600742

10.3171/jns.1994.81.6.0902

10.1111/j.1365-2559.2007.02800.x

10.1038/sj.bjc.6601727

10.1007/s10585-012-9469-1

10.1002/path.966

10.1046/j.1365-2559.2001.01061.x

10.1016/j.bbcan.2010.01.001

10.1042/BST20110650

10.1038/nature10144

10.1126/science.284.5422.1994

Kusters B., 2002, Vascular endothelial growth factor‐A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis, Cancer Res., 62, 341

10.1172/JCI0214105

10.1093/carcin/bgr076

10.1055/s-0031-1284381

10.1084/jem.20091846

10.1073/pnas.0914072107

10.1038/sj.bjc.6603039

10.1038/sj.bjc.6600015

10.1016/j.humpath.2008.11.008

10.1016/j.athoracsur.2007.08.054

10.1038/bjc.2011.579

10.1007/s10585-011-9428-2

10.1038/nm.2072

10.1002/nbm.1786

10.1038/sj.onc.1208242

10.1016/j.canlet.2010.09.004

10.1158/0008-5472.CAN-10-2602

10.1054/brst.1999.0082

10.1200/JCO.2011.38.7621

10.1038/sj.neo.7900102

10.1016/j.ccr.2012.05.037

10.1016/j.mam.2011.04.001

10.1245/s10434-011-1765-5

10.1158/1078-0432.CCR-04-0823

10.1093/jncimonographs/lgr027

10.2214/AJR.09.2941

10.1007/s10456-012-9291-z

10.1038/onc.2010.503

10.1158/0008-5472.CAN-11-1693

10.1158/0008-5472.CAN-11-3831

10.1038/nbt1323

10.1200/JCO.2012.44.4711

10.1016/j.cllc.2011.06.002

10.1586/era.12.111

10.1371/journal.pone.0005857

10.1002/glia.20850

10.1002/path.2484

10.1016/j.lungcan.2006.11.018

10.1007/s11060-004-5674-3

10.1158/1078-0432.CCR-05-1077

10.1002/ijc.20886

10.1111/j.1600-0714.2004.00252.x

10.1038/sj.bjc.6602134

10.1111/j.1365-2559.2004.01803.x

Kaicker S., 2003, Thalidomide is anti‐angiogenic in a xenograft model of neuroblastoma, Int. J. Oncol., 23, 1651

10.1002/ijc.11102

Thông tin
Thông tin xuất bản

Cancer Medicine

Tập 2 Số 4

427-436

Thông tin tác giả